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Schmallenberg virus, a novel orthobunyavirus, is 
spreading among ruminants, especially sheep, throughout 
Europe. To determine the risk for human infection, we 
conducted a survey among shepherds to assess possible 
exposure and symptoms. We also performed serologic and 
molecular assays. No evidence of transmission to humans 
was detected.
In November 2011, a new virus of the genus Orthobunyavirus was isolated from diseased cattle in 
Germany and was provisionally called Schmallenberg 
virus (SBV) (1). It has caused disease in ruminants, i.e., 
sheep, cattle, and goats. Acute clinical signs such as fever 
and diarrhea; severe congenital malformation, such as 
arthrogryposis and hydroencephaly; and a high proportion 
of stillbirths have been reported among infected animals 
(2). Transplacental transmission leads to fetal infection. 
The virus is vector borne and has been isolated from biting 
midges (Culicoides spp.) (3–5). Genomic analyses showed 
a close phylogenetic relationship to epizootic viruses of 
the Simbu serogroup, for which zoonotic transmission has 
not been shown (1). However, SBV also bears new genetic 
and animal-related clinical and epidemiologic properties. 
Iquitos and Oropouche viruses of this serogroup are also 
transmitted by culicoids and cause outbreaks in humans 
(6). La Crosse virus and California encephalitis virus 
can cause disease in humans and belong to the genus 
Orthobunyavirus. A few vector-borne zoonoses from the 
same family Bunyaviridae, i.e., Rift Valley fever virus and 
Crimean-Congo hemorrhagic fever virus, also are highly 
transmissible to humans through handling of infectious 
animal tissue. However, this mode of transmission has 
not been described for orthobunyaviruses. Shortly after 
its recognition, SBV and associated disease were reported 
from an increasing number of European countries, and 
further spread is conceivable. The virus currently is 
isolated mainly from sheep farms (7,8). In Germany, North 
Rhine-Westphalia is the area most affected. Viral loads 
are high in infected animals and their birth products (2). 
Thus, shepherds can be considered as strongly exposed, 
especially during animal obstetric events.
Because SBV emerged recently, transmission 
from animals to human cannot be completely excluded. 
Knowing whether SBV poses a risk to humans is vital. 
Therefore, we conducted a seroprevalence study among 
exposed shepherds in the area in Germany most affected 
(North Rhine-Westphalia) to determine whether zoonotic 
or vector-borne infections occur in humans.
The Study
At an SBV information meeting, 60 shepherds >18 
years of age were recruited for this study. After obtaining 
written informed consent, we administered a standardized 
questionnaire. We collected information about age, sex, 
SBV infection in their livestock, exposure to sick lambs, 
frequency of insect bites, personal health, and categories of 
signs of disease after exposure. In addition, a serum sample 
was taken from each participant.
We developed an indirect fl uorescent antibody test 
(IFAT) for primary testing of human serum. For this 
test, antihuman fl uorescein isothiocyanate–conjugated 
secondary antibodies against SBV-specifi c IgM or IgG 
(antibovine for positive control) were used. For the IFAT, 
all heat-inactivated serum specimens were tested in 
dilutions of 1:20 and 1:80 on glass slides with noninfected 
and SBV-infected Vero cells. An SBV antibody–positive 
serum sample from an experimentally infected cow was 
used as a positive control. To check for background signals 
and possible cross-reactivity, we tested 80 serum samples 
from healthy blood donors; none were positive. A serum 
neutralization test (SNT) was developed for confi rmation 
of indeterminate and positive results. Serial dilutions of 
the test serum (lowest dilution 1:5) were incubated for 1 
h at 37°C with an equal volume of cell culture supernatant 
containing 100 infectious doses of SBV and subsequently 
mixed with Vero cells. To detect SBV-specifi c RNA, 
we performed a 1-step real-time reverse transcription 
quantitative PCR (RT-qPCR) on serum, as described (1). 
The ethics committee of the University Medicine Charité 
Berlin approved our study.
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All 60 participants (75% male; median age 48 
years [interquartile range (IQR) 41–56 years]) reported 
sheep husbandry in the SBV-epizootic area (Table 1). 
Altogether, 48 (80%) participants had contact with 
lambs that had characteristic malformations or with the 
respective birth products (median 10 [IQR 4–20] sick 
lambs). In livestock from 36 (60%) participants, SBV was 
laboratory confi rmed. Characteristic signs among adult 
animals had fi rst been noted in September 2011. Median 
time from fi rst signs in animals to blood withdrawal was 
45 days (IQR 39–66 days). A total of 55 (98%) of 56 
participants self-reported insect bites during late summer 
to autumn; among these, 22 (39%) indicated frequent 
insect bites. Nine (15%) shepherds reported having had 
signs and symptoms since the disease had appeared in 
the study area or after handling diseased animals (Table 
1): myalgia and arthralgia (7 shepherds), headache (4), 
fever (4), skin rash (2), and respiratory problems (2). No 
shepherds reported hospitalization. Of the 36 shepherds 
whose livestock had laboratory-confi rmed SBV infection, 
5 (14%) reported signs and symptoms: myalgia and 
arthralgia (4 shepherds), headache (2), fever (2), skin rash 
(2), and respiratory problems (2).
No SBV-specifi c antibodies were detected in any 
serum specimens (Table 2) . Eight specimens showed 
indeterminate fl uorescent signals in the IFAT at a 1:20 
serum dilution for IgG (n = 1) or IgM (n = 7) but were not 
reactive at 1:80 (Figure). These 8 samples were retested by 
SNT (serum dilution 1:10) and showed no virus inhibition 
at any serum dilution during 7 days of incubation. Two 
(25%) of these 8 shepherds reported symptoms. For the 
bovine control serum, the titer of the SNT was 320. RT-
qPCR was negative in all serum samples.
Conclusions
We investigated the risk for human infection after 
possible high exposure to an emerging vector-borne 
epizootic disease through contact with infected animals 
and tissues or through insect bites. No evidence of SBV 
infection among the shepherds was found by molecular 
and serologic tests, even though most of the shepherds 
had received substantial exposure through repeated direct 
contact with sheep with laboratory-confi rmed SBV-
infection and with birth products known to contain high 
virus loads in the SBV-epizootic area. Reported symptoms 
were compatible with illnesses commonly experienced 
during the winter (i.e., infl uenza-like illness caused by 
human respiratory viruses) without considerable differences 
between the exposure categories. The likelihood of virus 
detection by RT-qPCR is certainly limited because SBV 
viremia in livestock lasts only a few days (4,8). Viremia 
could be of short duration in humans as well. However, 
after the end of the viremic phase, detection of specifi c 
antibodies can be expected. The period between exposure 
and sampling was suffi ciently long to for antibodies to have 
developed after infection. Furthermore, a large proportion 
of the participants indicated having been frequently bitten 
by insects in the epizootic area. Midge bites are diffi cult to 
recall, and therefore this exposure could not be assessed 
precisely. Recollection of insect bites might not be 
equivalent to exposure to the vector species. Although SBV 
has been isolated from certain midge species, entomologic 
knowledge about the ability of different midge species to 
transmit SBV, i.e., vector competence and host feeding 
behavior, is still scarce. Nevertheless, on the basis of 
results from our study and the phylogenetic relationship of 
SBV, we conclude that the novel virus is unlikely to pose 
a threat to humans by transmission from infected livestock 
or from midges.
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No. shepherds with 
symptoms/total no. 
exposed (%)‡ 
Sheep husbandry in SBV-epizootic area 60/60 (100) 9/60 (15) 
Laboratory-confirmed SBV infection in livestock 36/60 (60) 5/36 (14) 
Contact with birth products or with lambs that had characteristic signs of SBV disease 48/60 (80) 8/48 (17) 
Contact with adult sheep that had characteristic signs of SBV disease 28/51 (55) 5/28 (18) 
Frequent insect bites in SBV-epizootic area§ 22/56 (39) 5/22 (23) 
*SBV, Schmallenberg virus. 
†Multiple responses possible. 
‡Self-reported signs and symptoms of fever, headache, skin rash, myalgia/arthralgia, respiratory problems, or photophobia since SBV infection appeared 
in the study area or after handling diseased animals and resulting from unknown cause in each exposure category. 
§Self-reported as ‘”very often” or “often.” 
Table 2. Results of diagnostic tests for SBV in serum samples 
from exposed shepherds, Germany, 2012* 
Test system and dilution 
Test results, no. (%) 
Positive/total Indeterminate/total 
IFAT IgG 80 0/60  0/60  
IFAT IgM 80 0/60  0/60  
IFAT IgG 20 0/60  1/60 (2) 
IFAT IgM 20 0/60  7/60 (11) 
SNT titer 10† 0/8  0/8  
RT-qPCR 0/60  0/60  
*SBV, Schmallenberg virus; IFAT, indirect fluorescent antibody test; SNT, 
serum neutralization test; RT-qPCR, quantitative reverse transcription 
PCR. 
†Performed in only 8 serum samples with IFAT indeterminate results; 2/8 
(25%) reported symptoms as outlined in Table 1. 
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Figure. Fluorescent light microscopy images of serum samples tested for antibodies to Schmallenberg virus by indirect fl uorescent 
antibody test on infected Vero cells mixed with noninfected Vero cells. A) Nonreactive negative serum; B) positive serum reactive with 
infected cells only; C) indeterminate serum with faint nonspecifi c reactivity. A color version of this fi gure is available online (wwwnc.cdc.
gov/EID/article18/8/12-0533-F1.htm).
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